The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

NECTIN4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.

Niklas  Klümper

Stock and Other Ownership Interests  - Bicycle Therapeutics; Daiichi Sankyo/UCB Japan; immatics; Pfizer

Honoraria - Astellas Pharma; MSD Oncology

Consulting or Advisory Role - Astellas Pharma; Eisai; MSD Oncology

Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Photocure

Markus  Eckstein

Employment - Diaceutics

Honoraria - Astellas Pharma; AstraZeneca; Diaceutics; Genomic Health; Janssen-Cilag; Owkin; Roche

Consulting or Advisory Role - AstraZeneca; Diaceutics; Genomic Health; Gilead Sciences; Janssen-Cilag; MSD Oncology; Owkin

Speakers' Bureau - Astellas Pharma; AstraZeneca; Diaceutics; MSD; Roche

Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune; Gilead Sciences; Janssen; Owkin; STRATIFYER Molecular Pathology

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Diaceutics; Genomic Health; Janssen-Cilag; MSD; Roche

Petros  Grivas

Consulting or Advisory Role - Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; CG Oncology; Daiichi Sankyo; EMD Serono; Fresenius Kabi; Gilead Sciences; ImmunityBio; Janssen; Merck; Pfizer; Replimune; Roche; Strata Oncology

Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Mirati Therapeutics (Inst); QED Therapeutics (Inst)

Enrique  Grande

Stock and Other Ownership Interests  - PharmaMar

Honoraria - Abbott/AbbVie; Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; AVEO; Bristol-Myers Squibb; Dr. Reddy's Laboratories; Eisai; Eusa Pharma; EUSA Pharma; GlaxoSmithKline; IPSEN; Janssen-Cilag; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche

Consulting or Advisory Role - Abbvie; AVEO; Bristol-Myers Squibb; Gilead Sciences; Ipsen; MSD; Pfizer; Roche; Roche

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Merck KGaA (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech

Johannes  Brägelmann

Research Funding - Bayer

Jason  Hoffman

Employment - EMD Serono

Stock and Other Ownership Interests  - Merck; Merck & Co., Kenilworth, NJ, USA; Pfizer

Parantu  Shah

Employment - EMD Serono

Olga  Bogatyrova

Employment - Merck KGaA

Viktor  Grünwald

Employment - University Hospital Essen

Stock and Other Ownership Interests  - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD

Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer

Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine

Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer